title: Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
abstract: BACKGROUND
  Although men and women have similar diabetes prevalence, the same medicine will cause different therapeutic results in different genders. To understand the molecular mechanism, we explored the effects of a combined therapy of Exenatide and Metformin on obesity and overweight female and male patients with newly diagnosed type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks.
  
  
  RESULTS
  There was an average of 8.2 ± 2.4 kg and 4.6 ± 2.3 kg weight loss in female and male patients, respectively. The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05).
  
  
  CONCLUSIONS
  The combined therapy of Exenatide and MET shows better therapeutic results in female patients than in male patients. Therefore, the dual therapy is more suitable for female patients.
authors.affiliation: Department of Endocrinology, People's Hospital of Hainan Province, Haikou, Hainan 570311, China. Electronic address: quanhuibiao_2015@163.com.
authors.forename: Huibiao
authors.initials: H
authors.lastname: Quan
authors.affiliation: Endocrine Laboratory, People's Hospital of Hainan Province, Haikou, Hainan 570311, China.
authors.forename: Huachuan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, People's Hospital of Hainan Province, Haikou, Hainan 570311, China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Wei
authors.affiliation: Department of Endocrinology, People's Hospital of Hainan Province, Haikou, Hainan 570311, China.
authors.forename: Tuanyu
authors.initials: T
authors.lastname: Fang
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015992:Body Mass Index; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination / Q000009:adverse effects; D000077270:Exenatide; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D054795:Incretins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D050177:Overweight / Q000150:complications / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012727:Sex Characteristics; D014688:Venoms / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D008687:Metformin; D010455:Peptides; D014688:Venoms; C517652:hemoglobin A1c protein, human
keywords: Combination therapy; Exenatide; Gender difference; Metformin; Type 2 diabetes mellitus